Navigation Links
Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
Date:10/2/2009
LACHEN, Switzerland, Oct. 2 /PRNewswire/ -- Through June 2009, Octapharma AG realized a record turnover of 536 M euro, compared to 422 M euro as of year-to-date June 2008, an increase of 27%.
(Photo: http://www.newscom.com/cgi-bin/prnh/20091002/NY86257)
The cost of sales increased proportionally more than the turnover, decreasing gross margin from 46.4% to 43.3%, primarily due to increased plasma costs.
Due to increased efficacy in other areas, Octapharma reached a satisfactory level in its operating income through June 2009 (earnings before interest and taxes) of 173 M euro (32.3% margin), compared with 141 M euro (33.4% margin) in the same period of 2008.
Plasma Protein Industry's Outlook for the Second Half 2009 and 2010
In the area of plasma collection, the fact that plasma collection centers are closing on Saturdays and that the remaining independent plasma suppliers offer discounts confirms that there is an oversupply.
Declining prices in government and hospital tenders worldwide also point in this direction.
In spite of a continuous growth of 5% - 6% in the IVIG market we therefore expect monthly sales to stay at the present level with higher quantities the remaining part of 2009. 2010 will remain flat compared to 2009, again with higher unit sales.
A high pressure in many countries on the reimbursement structure will further contribute to the negative trend. However, the patients can on this basis experience a more stable supply of products with fewer interruptions. Octapharma intends to overcome the present trend by the launch of new products.
Headquartered in Lachen, Switzerland, Octapharma is the third largest plasma prod
'/>"/>
| SOURCE Octapharma AG Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
2. Pillar Capital Announces Acquisition of Medico Labs Assets
3. Cyberonics Announces Epilepsy Technology Collaborations
4. Bionovo Announces Pricing of Securities Offering
5. Winner Medical Announces Two-for-One Reverse Stock Split
6. DST Systems, Inc. Announces Exchange Transaction Involving 4.125% Series A Convertible Senior Debentures
7. Healthcare Realty Trust Announces New $550 Million Unsecured Revolving Credit Facility
8. Lumetra Announces Sale of Subsidiary IntegriGuard
9. UCSF Announces Expanded BreastCancerTrials.org Website
10. DSS Research Announces Senior Health Risk Assessment (SrHRA)(TM)
11. US Farms, Inc. Announces Distribution Partnership With Natures Best
Post Your Comments:
(Date:5/22/2013)... 22, 2013 GS1 has honored Tim ... Company, and Danny Wegman, CEO, Wegmans Food Markets, ... General Assembly and Global Leadership Summit, held May 20-23 ... were recognized for their outstanding contributions to the advancement ... used supply chain standards globally. , “The leadership, ...
(Date:5/22/2013)... and teens exposed to radiation during CT scans are ... a large, long-term study. The risks, however, are ... who each had one CT scan, only about six ... years, according to researchers from Australia and Europe. ... to patients when making decisions about CT (computed tomography) ...
(Date:5/22/2013)... This news release is available in German . ... Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 11 new ... in Germany. This decision was made by the relevant ... euros has been awarded to the new programmes for ... In addition to the 11 new Research Training Groups, ...
(Date:5/22/2013)... to finish the last ounce in their bottle might be ... burn off, a bad habit remains. , Brigham Young University ... obesity at 24 months of age strongly traces back to ... it puts you on a trajectory where you are likely ... an adult," said Forste. "That,s a big concern." , The ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal ... the previous version used prior to 2010, the 7-valent ... study published today in Vaccine . , The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine News(10 mins):Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Children Who Have CT Scans May Face Higher Cancer Risk 2Health News:DFG establishes 11 new research training groups 2Health News:DFG establishes 11 new research training groups 3Health News:DFG establishes 11 new research training groups 4Health News:DFG establishes 11 new research training groups 5Health News:Overeating learned in infancy, study suggests 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2[0] Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards[0] Children Who Have CT Scans May Face Higher Cancer Risk[0] DFG establishes 11 new research training groups[0] Overeating learned in infancy, study suggests[0] Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
... Concerns of citizens over the poisonous vegetables found in ... voluntary registration system// for local farms. Additionally, supermarket chains ... a comprehensive tracking system for farm produce, according to ... system has been pointed out by a Hong Kong's ...
... Gen. Nadeem Ahmed, deputy chairman, Earthquake Rehabilitation and ... that would enable Pakistan recover from the devastating ... be completed within a year, covering some reconstruction ... distribution system, water and sanitation system, skill training, ...
... Pramod Mahajan is currently critical after being shot by his ... residence.// Pramod is currently being ventilated in the Intensive Care ... , ,Mr.Mahajan, a known diabetic received four bullets which ... at close range and went through the liver, shattering its ...
... Cancer Screening Programme, which will cover the country over the ... welcomed the introduction of this program. ... is now official that funds are being made available for ... the President of the Society as well as the Director ...
... appoint a senior nurse so that the elderly are treated ... by the government. // Ministers said there would be an ... patients in the hospitals. <br,Professor Ian Philp, the government's ... subjected to rigorous checks in order to ensure that they ...
... Piper, a New Zealander says that he was forced to take ... wife received her medications. // He says the local DHB began ... to take her from the hospital unless provided with the drug. ... only one, which controls her nausea. The Hawke's Bay hospital refused ...
Cached Medicine News:Health News:Review of Pramod Mahajan's Injuries 2(Date:5/22/2013)... -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it ... enrollment required for its Phase I trial to evaluate the ... Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common ... no Severe Adverse Effect (SAE) reported. The Phase ... NIH under number NCT01828762 (click here to view) ...
(Date:5/22/2013)... May 22, 2013 PRNewswire – iBio, ... of a vaccine candidate for the newly emerged ... laboratory using the iBioLaunch™ platform. This validation milestone ... initial antigen sequence information to purification of recombinant ... ) The iBioLaunch platform eliminates the ...
(Date:5/22/2013)... TEL AVIV, Israel , May 22, 2013 /PRNewswire/ ... "Company") (TASE, NASDAQ: EMITF) announced today, further to the ... filed a motion with the Tel Aviv ... of its unsecured creditors and shareholders for the approval ... debt pursuant to a plan of arrangement (the "Arrangement") ...
Breaking Medicine Technology:Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 2Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court 3[0] Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer[0] iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza[0] Elbit Imaging Announces the Court Decision with Respect to Filing of Plan of Arrangement with the Israeli Court
... Pa., Aug. 24, 2011 ePharmaSolutions announced the successful ... for a top five global pharmaceutical company on more ... client deployment scheduled for September 2011. Clinical ... process for sponsors, study sites and third party vendors ...
... Fla., Aug. 24, 2011 China Nuvo Solar ... various sales channels are all reporting success that is ... lines. The Company,s plan of action to sell through ... with medical co-ops and other third party outsourcing solutions ...
Cached Medicine Technology:ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies 2China Nuvo Solar Target Acquisition SurgLine Reports on Marketing Progress 2China Nuvo Solar Target Acquisition SurgLine Reports on Marketing Progress 3BD Visitec IOL Manipulator (Sinskey), blunt tip angled 45, 15.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles han...
Hunkeler lens manipulator, angled. Also available in titanium....
Sinskey lens manipulator, straight. Also available in titanium....
ICL manipulator with textured hemi-ball tip...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |